Holen Sie sich die Stockscreener-App
18.76
1.63%
-0.31
Schlusskurs vom Vortag:
$19.07
Offen:
$19.23
24-Stunden-Volumen:
29,638
Relative Volume:
0.75
Marktkapitalisierung:
$64.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.92M
KGV:
-2.6793
EPS:
-7.0019
Netto-Cashflow:
$-17.78M
1W Leistung:
+6.77%
1M Leistung:
+66.61%
6M Leistung:
-75.18%
1J Leistung:
-68.68%
1-Tages-Spanne:
$17.17
$19.23
1-Wochen-Bereich:
$16.80
$19.96
52-Wochen-Spanne:
$8.20
$19.96
Eloxx Pharmaceuticals Inc Stock (ELOX) Company Profile
Firmenname
Eloxx Pharmaceuticals Inc
Sektor
Branche
Telefon
781-577-5300
Adresse
P.O. BOX 274, ARLINGTON
Compare ELOX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELOX
Eloxx Pharmaceuticals Inc
|
18.76 | 62.76M | 0 | -17.92M | -17.78M | -7.0019 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eloxx Pharmaceuticals Inc Stock (ELOX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Eingeleitet | B. Riley Securities | Buy |
| 2020-06-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-06 | Eingeleitet | Janney | Buy |
| 2018-12-24 | Eingeleitet | H.C. Wainwright | Neutral |
| 2018-07-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Eloxx Pharmaceuticals Inc Aktie (ELOX) Neueste Nachrichten
Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate - Stock Titan
Nantahala Capital discloses 9.91% Eloxx Pharmaceuticals (ELOX) ownership in Schedule 13G - Stock Titan
LifeSci Capital Maintains Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Eloxx Pharmaceuticals Q2 net loss widens on higher expenses - TradingView
Eloxx Plans Phase 2b Alport Trial in Q3 After ~$66M Offering - Stock Titan
Form 8K Eloxx Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Eloxx Pharmaceuticals reports Q2 2026 net loss $4.5M, $62.0M cash after $66.0M offering - TradingView
Eloxx Pharmaceuticals, Inc. 2Q 2026: Net loss $4.5M, EPS $(0.66) — 10-Q Summary - TradingView
ELOX: Raised $58.3M in public offering, advancing exaluren trials amid rising operating losses - TradingView
Eloxx Pharmaceuticals Ord Shs (ELOX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Biotech Stocks At 52-Week HighsANGO, ANIK, ELOX, YARW, PLSE - RTTNews
Eloxx Pharmaceuticals (ELOXD) Financials 2026Income Statement and Balance Sheet - MarketBeat
abrdn Inc. (ELOX) discloses 400,000-share, 9.91% holding in Eloxx - Stock Titan
ELOX|Eloxx Pharmaceuticals Ord Shs|Price:11.940|Chg%:-0.060 - TradingKey
Eloxx Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELOX - TradingView
Enterprise value to EBIT forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
Price to earnings forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
ELOX stock holds on report context and clinical milestones - Ad-hoc-news.de
Eloxx Pharmaceuticals (ELOX) Q4 2025 earnings summary - Quartr
Eloxx Pharmaceuticals (ELOX) Registration filing Summary - Quartr
Eloxx Pharmaceuticals (ELOX) Q1 2026 earnings summary - Quartr
LifeSci Capital Initiates Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Announces Target Price $40 - Moomoo
Guggenheim Initiates Eloxx Pharmaceuticals at Buy With $43 Price Target - marketscreener.com
Eloxx Pharmaceuticals initiated with a Buy at Guggenheim - TipRanks
Guggenheim initiates Eloxx Pharma stock with buy on kidney data By Investing.com - Investing.com Canada
Guggenheim Initiates Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Announces Target Price $43 - Moomoo
ELOX Price Today: Eloxx Pharmaceuticals, Inc. Stock Price, Quote & Chart - mexc.co
Eloxx Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
Price to book forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
ELOX stock trades on Nasdaq as small-cap biotech focuses on cystic fibrosis therapy - Ad-hoc-news.de
ELOX|Eloxx Pharmaceuticals Ord Shs|Price:12.270|Chg%:+1.320 - TradingKey
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq - AOL.com
Price to sales forward of Eloxx Pharmaceuticals, Inc. – BOATS:ELOX - TradingView
Enterprise value to EBITDA forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
Eloxx Pharma (ELOX) Stock Analysis Report | Financials & Insights - Benzinga España
Eloxx’s EXACT Study Puts Exaluren in Focus for Rare Kidney Disease Investors - TipRanks
ELOXEloxx Pharmaceuticals Inc Latest SEC Filings - Finviz
Enterprise value to revenue forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
ELOX SEC FilingsEloxx Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Eloxx Pharmaceuticals StockSaturday view on pipeline and business model - AD HOC NEWS
Coastlands (NASDAQ: ELOX) discloses 410,530 shares, 9.99% stake - Stock Titan
Domicilium group discloses 19.99% stake in Eloxx (NASDAQ: ELOX) - Stock Titan
Eloxx (ELOX) 10% holder swaps Pre-Funded Warrants into common stock - Stock Titan
Domicilium Real Estate Fund III (ELOX) details Eloxx stock and warrant stakes - Stock Titan
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
EcoR1, affiliates report ~9.9% holdings in Eloxx (NASDAQ: ELOX) - Stock Titan
Stonepine-affiliated holders report 403,228 shares in Eloxx (ELOX) — 9.9% stake - Stock Titan
Invus-led group holds 9.99% of Eloxx (ELOX) via shares and warrants - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Eloxx Pharmaceuticals: Shares Expected to Start Trading on Nasdaq Capital Market on June 9 >ELOX - Moomoo
ELOX Technical Analysis & ETF Price Forecast - Intellectia AI
Finanzdaten der Eloxx Pharmaceuticals Inc-Aktie (ELOX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):